Q-linea, Setting Sights on Clinical Dx Market, Aims to Launch Antibiotic Susceptibility Test by 2015 | GenomeWeb

UPPSALA, Sweden — Swedish technology firm Q-linea hopes to deliver to market within the next three years a clinical assay that can identify bacteria responsible for sepsis and determine its susceptibility to antibiotics.

CEO Jonas Jarvius said that the privately held company is "putting all of its focus" on the diagnostics market, looking to parlay its nucleic acid- and protein-detection capabilities into a steady revenue stream from hospitals that would use the test to select the most effective antibiotics regimens for patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.